PCI-32765 (Ibrutinib) in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-cell Prolymphocytic Leukemia

Clinical trial NCT01589302 · ACTIVE_NOT_RECRUITING

Trial details

NCT number

NCT01589302

Sponsor

Kami Maddocks, MD

Status

ACTIVE_NOT_RECRUITING

Phase

Phase 2

Study type

INTERVENTIONAL

Start date

2012-05-21

Primary completion

2016-07-28

Enrollment

154

View on ClinicalTrials.gov